Sjoerd H. Hofma - Concepedia

Author

Sjoerd H. Hofma

Also Known As

Hafid Amrane, James C. Spratt, Pieter Smits, Robert G Xuereb, S H Hofma, S Hofma, S. H. Hofma, S.H Hofma, S.H. Hofma, SJOERD H. HOFMA

142

Publications

15.6K

Citations

H-Index

Concepts

All Affiliations

Medisch Centrum Leeuwarden Erasmus University Rotterdam Imperial College London Erasmus MC Maasstad Ziekenhuis

About

Sjoerd H. Hofma is an author at Medisch Centrum Leeuwarden specializing in medicine, cardiovascular disease, and coronary heart disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	27	3.5K
2	Emergency Medicine	7	7	917
3	Biomedical Engineering	5	5	515
4	Public Health	4	4	175
5	Diabetes	1	1	78

Sjoerd H. Hofma

Publications

7.2K

Citations

H-Index

Page 1

	Year	Citations
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial Pascal Vranckx, Marco Valgimigli, Peter Jüni, The Lancet Endovascular TechniqueCardiovascular DiseaseRandomised Superiority TrialLumen-apposing Metal StentPharmacotherapy	2018	761
Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents Patrick W. Serruys, Sigmund Silber, Scot Garg, New England Journal of Medicine	2010	656
Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the “Real World” Pedro A. Lemos, Patrick W. Serruys, Ron T. van Domburg, Circulation	2003	543
Bioresorbable Scaffolds versus Metallic Stents in Routine PCI Joanna J. Wykrzykowska, Robin P. Kraak, Sjoerd H. Hofma, New England Journal of Medicine	2017	426
Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation Sjoerd H. Hofma, Wim J. van der Giessen, Bas M. van Dalen, European Heart Journal	2005	385
Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial Marieke E. Gimbel, Khalid Qaderdan, Laura M. Willemsen, The Lancet ThrombosisPopular AgeCardiovascular DiseaseClopidogrel Versus TicagrelorNon-inferiority Trial	2020	342
Clinical, Angiographic, and Procedural Predictors of Angiographic Restenosis After Sirolimus-Eluting Stent Implantation in Complex Patients Pedro A. Lemos, Angela Hoye, Dick Goedhart, Circulation	2004	332
Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial Pieter C. Smits, Sjoerd H. Hofma, Mario Togni, The Lancet Compare IiVascular SurgeryLumen-apposing Metal StentSurgeryNon-inferiority Trial	2013	289
Coronary Restenosis After Sirolimus-Eluting Stent Implantation Pedro A. Lemos, Francesco Saia, Jürgen Ligthart, Circulation	2003	286
Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction—TROFI II trial Manel Sabaté, Stephan Windecker, Andrés Íñiguez, European Heart Journal	2015	219

Page 1